|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US7063967B2
(en)
|
1997-05-08 |
2006-06-20 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
|
US6764840B2
(en)
|
1997-05-08 |
2004-07-20 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
|
AU773921B2
(en)
*
|
1997-05-08 |
2004-06-10 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
|
US6303347B1
(en)
*
|
1997-05-08 |
2001-10-16 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
|
US7541020B2
(en)
*
|
1997-05-08 |
2009-06-02 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US7083796B2
(en)
*
|
2000-06-20 |
2006-08-01 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
|
ID30407A
(id)
*
|
1999-05-13 |
2001-11-29 |
American Cyanamid Co |
Formulasi-formulasi kombinasi bahan penambah
|
|
WO2001024820A1
(en)
*
|
1999-10-07 |
2001-04-12 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
|
CZ303468B6
(cs)
|
2000-02-23 |
2012-10-03 |
Smithkline Beecham Biologicals S. A. |
Imunogenní smes a farmaceutická smes
|
|
AU2001241738A1
(en)
*
|
2000-02-25 |
2001-09-03 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US6699846B2
(en)
*
|
2000-03-17 |
2004-03-02 |
Corixa Corporation |
Mono- and disaccharides for the treatment of nitric oxide related disorders
|
|
WO2001078777A2
(en)
*
|
2000-04-13 |
2001-10-25 |
Mossman, Sally |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
|
|
US20030139356A1
(en)
*
|
2001-05-18 |
2003-07-24 |
Persing David H. |
Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
|
|
EP2000144A1
(en)
*
|
2000-05-19 |
2008-12-10 |
Corixa Corporation |
Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds
|
|
US20030105032A1
(en)
*
|
2000-05-19 |
2003-06-05 |
Persing David H. |
Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds
|
|
US7129219B2
(en)
|
2000-08-04 |
2006-10-31 |
Corixa Corporation |
Immunoeffector compounds
|
|
HUP0600589A2
(en)
*
|
2000-11-10 |
2006-11-28 |
Wyeth Corp |
Adjuvant combination formulations
|
|
US20060142202A1
(en)
*
|
2000-12-08 |
2006-06-29 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
|
ES2359625T3
(es)
|
2000-12-28 |
2011-05-25 |
Wyeth Llc |
Proteina protectora recombinante de.
|
|
BR0208874A
(pt)
*
|
2001-04-13 |
2004-06-22 |
Wyeth Corp |
Proteìnas superficiais de streptococcus pyogenes
|
|
US20070128229A1
(en)
*
|
2002-04-12 |
2007-06-07 |
Wyeth |
Surface proteins of Streptococcus pyogenes
|
|
WO2002083855A2
(en)
|
2001-04-16 |
2002-10-24 |
Wyeth Holdings Corporation |
Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
|
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
|
US7030094B2
(en)
*
|
2002-02-04 |
2006-04-18 |
Corixa Corporation |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
|
|
US20030190333A1
(en)
*
|
2002-02-04 |
2003-10-09 |
Corixa Corporation |
Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
|
|
RU2288723C2
(ru)
*
|
2002-02-04 |
2006-12-10 |
Корикса Корпорейшн |
Профилактическое и терапевтическое лечение инфекционных и других заболеваний с помощью иммуноэффективных соединений
|
|
RU2289585C2
(ru)
*
|
2002-02-04 |
2006-12-20 |
Корикса Корпорейшн |
Новые аминоалкилглюкозаминидфосфатные соединения, иммуностимулирующая фармацевтическая композиция, их содержащая, и способ индуцирования иммунного ответа
|
|
US6911434B2
(en)
*
|
2002-02-04 |
2005-06-28 |
Corixa Corporation |
Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
|
|
EP1482795B1
(en)
*
|
2002-02-04 |
2009-11-11 |
Corixa Corporation |
New immunoeffector compounds
|
|
JP2005523902A
(ja)
|
2002-02-04 |
2005-08-11 |
コリクサ コーポレイション |
感染症及び他の疾患の免疫効果化合物による予防及び治療処理
|
|
US7026465B2
(en)
|
2002-02-15 |
2006-04-11 |
Corixa Corporation |
Fusion proteins of Mycobacterium tuberculosis
|
|
US7351413B2
(en)
*
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
|
NZ534566A
(en)
*
|
2002-02-22 |
2007-02-23 |
3M Innovative Properties Co |
Method of reducing and treating UVB-induced immunosuppression
|
|
WO2003073827A2
(en)
*
|
2002-02-28 |
2003-09-12 |
Corixa Corporation |
Methods of modulating dendritic cells using adjuvants
|
|
NZ535754A
(en)
|
2002-03-15 |
2007-01-26 |
Wyeth Corp |
Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
|
|
US7820627B2
(en)
*
|
2002-05-09 |
2010-10-26 |
Oncothyreon Inc. |
Lipid A and other carbohydrate ligand analogs
|
|
RU2340621C2
(ru)
*
|
2002-07-08 |
2008-12-10 |
Корикса Корпорейшн |
Способы получения аминоалкилглюкозаминидфосфатов и дисахаридных иммуноэффекторов и их промежуточных соединений
|
|
US7288640B2
(en)
*
|
2002-07-08 |
2007-10-30 |
Corixa Corporation |
Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
|
|
US7785608B2
(en)
*
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
|
US7301554B2
(en)
*
|
2002-09-20 |
2007-11-27 |
Ricoh Company, Ltd. |
Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
|
|
AU2003300184B8
(en)
|
2002-12-30 |
2009-12-03 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
|
CA2512108C
(en)
*
|
2003-01-06 |
2013-04-02 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
JP2006517974A
(ja)
*
|
2003-02-13 |
2006-08-03 |
スリーエム イノベイティブ プロパティズ カンパニー |
Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
|
|
US7485432B2
(en)
*
|
2003-02-27 |
2009-02-03 |
3M Innovative Properties Company |
Selective modulation of TLR-mediated biological activity
|
|
US8110582B2
(en)
|
2003-03-04 |
2012-02-07 |
3M Innovative Properties Company |
Prophylactic treatment of UV-induced epidermal neoplasia
|
|
MXPA05009694A
(es)
*
|
2003-03-13 |
2005-10-20 |
3M Innovative Properties Co |
Metodos para mejorar la calidad de la piel.
|
|
AU2004220465A1
(en)
|
2003-03-13 |
2004-09-23 |
3M Innovative Properties Company |
Method of tattoo removal
|
|
US20040192585A1
(en)
*
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
|
AU2004244962A1
(en)
*
|
2003-04-10 |
2004-12-16 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds using metal-containing particulate support materials
|
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
|
CA2534625A1
(en)
*
|
2003-08-05 |
2005-02-24 |
3M Innovative Properties Company |
Infection prophylaxis using immune response modifier compounds
|
|
BRPI0413558A
(pt)
|
2003-08-12 |
2006-10-17 |
3M Innovative Properties Co |
compostos contendo imidazo substituìdo por hidroxilamina
|
|
AU2004266162A1
(en)
*
|
2003-08-25 |
2005-03-03 |
3M Innovative Properties Company |
Immunostimulatory combinations and treatments
|
|
MXPA06002199A
(es)
|
2003-08-27 |
2006-05-22 |
3M Innovative Properties Co |
Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi.
|
|
CA2537763A1
(en)
*
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for cd5+ b cell lymphoma
|
|
CA2540541C
(en)
|
2003-10-03 |
2012-03-27 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
|
EP1680080A4
(en)
*
|
2003-10-31 |
2007-10-31 |
3M Innovative Properties Co |
NEUTROPHILIC ACTIVATION THROUGH COMPOUNDS TO MODIFY THE IMMUNE RESPONSE
|
|
WO2005048945A2
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazo ring compounds
|
|
US7897767B2
(en)
|
2003-11-14 |
2011-03-01 |
3M Innovative Properties Company |
Oxime substituted imidazoquinolines
|
|
WO2005051317A2
(en)
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
|
US8940755B2
(en)
*
|
2003-12-02 |
2015-01-27 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
|
EP2336147B1
(en)
|
2003-12-17 |
2014-04-30 |
Janssen Alzheimer Immunotherapy |
A beta immunogenic peptide carrier conjugates and methods of producing same
|
|
AR046960A1
(es)
|
2003-12-17 |
2006-01-04 |
Wyeth Corp |
Metodos para producir los conjugados portadores de peptidos inmunogenicos
|
|
JP2007517035A
(ja)
|
2003-12-29 |
2007-06-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
|
|
JP2007517055A
(ja)
*
|
2003-12-30 |
2007-06-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答の増強
|
|
EP1699788A2
(en)
|
2003-12-30 |
2006-09-13 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
|
|
WO2005094531A2
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
|
CA2564855A1
(en)
*
|
2004-04-28 |
2005-10-28 |
3M Innovative Properties Company |
Compositions and methods for mucosal vaccination
|
|
GB0410220D0
(en)
|
2004-05-07 |
2004-06-09 |
Kirkham Lea Ann |
Mutant pneumolysin proteins
|
|
BRPI0511429A
(pt)
|
2004-05-21 |
2007-12-11 |
Wyeth Corp |
proteìna de ligação à fibronectina (fnb) isolada, alterada de staphylococcal aureus (s. aureus); fnb isolada, alterada; composição imunogênica; método para imunizar um vertebrado contra s. aureus; vetor de expressão; célula hospedeira recombinante; método para produzir uma fnb alterada; método para induzir uma resposta imunológica em um vertebrado; proteìna isolada, alterada de ligação à fibronectina (fnb) de staphylococcal aureus (s. aureus); e molécula isolada de ácido nucléico que codifica uma fnb alterada de s. aureus
|
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
|
US7915281B2
(en)
|
2004-06-18 |
2011-03-29 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
|
|
US7897609B2
(en)
|
2004-06-18 |
2011-03-01 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
|
US8026366B2
(en)
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
|
WO2006026470A2
(en)
*
|
2004-08-27 |
2006-03-09 |
3M Innovative Properties Company |
Hiv immunostimulatory compositions
|
|
EP1804583A4
(en)
*
|
2004-10-08 |
2009-05-20 |
3M Innovative Properties Co |
ADJUVANT FOR DNA VACCINE
|
|
US8445000B2
(en)
|
2004-10-21 |
2013-05-21 |
Wyeth Llc |
Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
|
|
JP5543068B2
(ja)
|
2004-12-30 |
2014-07-09 |
スリーエム イノベイティブ プロパティズ カンパニー |
キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
|
|
AU2005326708C1
(en)
|
2004-12-30 |
2012-08-30 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
|
CA2594253C
(en)
|
2004-12-30 |
2015-08-11 |
3M Innovative Properties Company |
Treatment for cutaneous metastases
|
|
WO2006084251A2
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune reponse modifiers
|
|
CA2597587A1
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
|
JP2008535832A
(ja)
|
2005-04-01 |
2008-09-04 |
コーリー ファーマシューティカル グループ，インコーポレイテッド |
ピラゾロピリジン−１，４−ジアミン、およびそのアナログ
|
|
JP2008538550A
(ja)
|
2005-04-01 |
2008-10-30 |
コーリー ファーマシューティカル グループ，インコーポレイテッド |
ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての１−置換ピラゾロ（３，４−ｃ）環状化合物
|
|
CA2604363C
(en)
|
2005-04-08 |
2015-06-16 |
Wyeth |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
US7709001B2
(en)
|
2005-04-08 |
2010-05-04 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
JP2008539252A
(ja)
*
|
2005-04-25 |
2008-11-13 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫活性化組成物
|
|
US20080213318A1
(en)
*
|
2005-07-05 |
2008-09-04 |
Hawaii Biotech, Inc. |
Malaria MSP-1 C-terminal enhanced subunit vaccine
|
|
PL1973564T3
(pl)
|
2005-12-22 |
2017-04-28 |
Glaxosmithkline Biologicals S.A. |
Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
|
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
EP1988896A4
(en)
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
|
MY148405A
(en)
|
2006-03-30 |
2013-04-30 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
EP2032719A2
(en)
|
2006-06-02 |
2009-03-11 |
GlaxoSmithKline Biologicals S.A. |
Method for identifying whether a patient will be responder or not to immunotherapy
|
|
US7906506B2
(en)
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
|
ES2437082T3
(es)
|
2006-07-18 |
2014-01-08 |
Glaxosmithkline Biologicals S.A. |
Vacunas contra la malaria
|
|
WO2008012538A2
(en)
|
2006-07-25 |
2008-01-31 |
The Secretary Of State For Defence |
Live vaccine strains of francisella
|
|
PL2086582T3
(pl)
|
2006-10-12 |
2013-04-30 |
Glaxosmithkline Biologicals Sa |
Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
|
|
AU2007353317B2
(en)
*
|
2006-11-15 |
2012-09-06 |
Eli Lilly And Company |
Methods and compositions for treating influenza
|
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
|
HRP20161606T1
(hr)
|
2007-03-02 |
2017-01-13 |
Glaxosmithkline Biologicals Sa |
Novi postupak i pripravci
|
|
ES2621211T3
(es)
|
2007-04-04 |
2017-07-03 |
Infectious Disease Research Institute |
Composiciones inmunogénicas que comprenden polipéptidos de mycobacterium tuberculosis y fusiones de los mismos
|
|
US9452209B2
(en)
|
2007-04-20 |
2016-09-27 |
Glaxosmithkline Biologicals Sa |
Influenza vaccine
|
|
SI2167121T1
(sl)
|
2007-06-26 |
2015-12-31 |
Glaxosmithkline Biologicals S.A. |
Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
|
|
EP2173376B1
(en)
*
|
2007-08-02 |
2015-03-25 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope influenza vaccines
|
|
CA2699853A1
(en)
|
2007-09-17 |
2009-03-26 |
Oncomethylome Sciences Sa |
Improved detection of mage-a expression
|
|
US20090215710A1
(en)
*
|
2007-09-24 |
2009-08-27 |
Reliance Life Sciences Pvt. Ltd. |
Carbohydrate based toll-like receptor (tlr) antagonists
|
|
ES2626634T3
(es)
|
2007-12-19 |
2017-07-25 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Formas solubles de la glucoproteína F del virus de Hendra y Nipah y usos de la misma
|
|
JP2011507523A
(ja)
*
|
2007-12-21 |
2011-03-10 |
ワイス・エルエルシー |
遺伝子改変した弱毒化水疱性口内炎ウイルス、組成物およびその使用方法
|
|
PL2222710T3
(pl)
|
2007-12-24 |
2017-01-31 |
Id Biomedical Corporation Of Quebec |
Rekombinowane antygeny rsv
|
|
BRPI0911195A2
(pt)
|
2008-04-09 |
2017-06-20 |
The Univ Of North Caroline At Chapel Hill |
métodos de regulação de arranjo de citoesqueleto de actina e formação de gap intracelular
|
|
SI2271360T1
(sl)
|
2008-04-16 |
2015-12-31 |
Glaxosmithkline Biologicals S.A. |
Cepivo
|
|
WO2009155484A2
(en)
|
2008-06-20 |
2009-12-23 |
Wyeth |
Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
|
|
BRPI0921286B8
(pt)
|
2008-11-05 |
2022-10-25 |
Wyeth Llc |
Composição imunogênica com múltiplos componentes para a prevenção de doença por estreptococos beta-hemolíticos (bhs).
|
|
US20110236470A1
(en)
|
2008-12-03 |
2011-09-29 |
Yaffa Mizrachi Nebenzahl |
GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
|
|
CA2748038A1
(en)
*
|
2008-12-23 |
2010-07-01 |
Glaxosmithkline Biologicals S.A. |
Method for inducing a trif-bias
|
|
WO2010079081A1
(en)
|
2009-01-07 |
2010-07-15 |
Glaxosmithkline Biologicals S.A. |
Methods for recovering a virus or a viral antigen produced by cell culture
|
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
|
CA2750055A1
(en)
|
2009-02-06 |
2010-08-12 |
Glaxosmithkline Biologicals S.A. |
Method for purifying viruses using a density gradient
|
|
AR075437A1
(es)
|
2009-02-17 |
2011-03-30 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamento
|
|
CA2755734A1
(en)
|
2009-03-17 |
2010-09-23 |
Gaetan Otto |
Improved detection of gene expression
|
|
BRPI1010516A2
(pt)
*
|
2009-04-09 |
2015-08-25 |
Univ North Carolina |
Métodos de tratamento de edema relacionados à isquemia-reperfusão
|
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
|
BRPI1011753B8
(pt)
|
2009-06-22 |
2021-05-25 |
Wyeth Llc |
conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
|
|
HUE036372T2
(hu)
|
2009-06-22 |
2018-07-30 |
Wyeth Llc |
Staphylococcus aureus antigének immunogén készítményei
|
|
AU2010264686A1
(en)
|
2009-06-24 |
2012-01-19 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
|
MX2012000035A
(es)
|
2009-06-24 |
2012-02-28 |
Id Biomedical Corp Quebec |
Antigenos de virus de sincicio respiratorio recombinantes.
|
|
US9907746B2
(en)
|
2009-07-06 |
2018-03-06 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
|
AU2010270722B2
(en)
|
2009-07-06 |
2015-06-04 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
|
EP4218799A1
(en)
|
2009-07-15 |
2023-08-02 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
|
GB0917457D0
(en)
|
2009-10-06 |
2009-11-18 |
Glaxosmithkline Biolog Sa |
Method
|
|
US9341623B2
(en)
|
2009-09-25 |
2016-05-17 |
Glaxosmithkline Biologicals Sa |
Immunodiffusion assay for influenza virus
|
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
|
US20130039943A1
(en)
|
2010-05-03 |
2013-02-14 |
Bruno Rene Andre |
Novel method
|
|
GB201009273D0
(en)
|
2010-06-03 |
2010-07-21 |
Glaxosmithkline Biolog Sa |
Novel vaccine
|
|
PT2575870T
(pt)
|
2010-06-04 |
2017-02-10 |
Wyeth Llc |
Formulações de vacinas
|
|
MX342138B
(es)
|
2010-07-06 |
2016-09-14 |
Variation Biotechnologies Inc |
Composiciones y metodos para el tratamiento de influenza.
|
|
KR101594228B1
(ko)
|
2010-08-23 |
2016-02-15 |
와이어쓰 엘엘씨 |
네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
|
|
NZ607224A
(en)
|
2010-09-10 |
2014-11-28 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
|
GB201101331D0
(en)
|
2011-01-26 |
2011-03-09 |
Glaxosmithkline Biolog Sa |
Compositions and uses
|
|
PL2651436T3
(pl)
|
2010-12-14 |
2016-10-31 |
|
Kompozycja antygenów mykobakteryjnych
|
|
DK2654784T3
(en)
|
2010-12-22 |
2017-02-13 |
Wyeth Llc |
STABLE IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES
|
|
CA2862864C
(en)
|
2011-01-13 |
2018-12-11 |
Variation Biotechnologies Inc. |
Compositions and methods for treating viral infections
|
|
CA2828068C
(en)
|
2011-02-22 |
2019-03-19 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
|
KR20140023903A
(ko)
|
2011-02-24 |
2014-02-27 |
온코타이레온, 인코포레이티드 |
항원보강제를 갖는 muc1 기초 당지질펩티드 백신
|
|
DK2707385T3
(da)
|
2011-05-13 |
2017-11-20 |
Glaxosmithkline Biologicals Sa |
RSV-F-præfusionsantigener
|
|
WO2012156391A1
(en)
|
2011-05-17 |
2012-11-22 |
Glaxosmithkline Biologicals S.A. |
Vaccine against streptococcus pneumoniae
|
|
WO2012167088A1
(en)
|
2011-06-03 |
2012-12-06 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
|
EP3153180A1
(en)
|
2011-06-03 |
2017-04-12 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
|
ITMI20111182A1
(it)
|
2011-06-28 |
2012-12-29 |
Canio Buonavoglia |
Vaccino per coronavirus canino
|
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
GB201116248D0
(en)
|
2011-09-20 |
2011-11-02 |
Glaxosmithkline Biolog Sa |
Liposome production using isopropanol
|
|
GB201119999D0
(en)
|
2011-11-20 |
2012-01-04 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
GB201120000D0
(en)
|
2011-11-20 |
2012-01-04 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
US20140356399A1
(en)
|
2012-01-12 |
2014-12-04 |
Variation Biotechnologies, Inc. |
Compositions and methods for treating viral infections
|
|
US20150079077A1
(en)
|
2012-01-27 |
2015-03-19 |
Variation Biotechnologies, Inc. |
Methods and compositions for therapeutic agents
|
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
|
MX359256B
(es)
|
2012-03-09 |
2018-09-19 |
Pfizer |
Composiciones de neisseria meningitidis y metodos de las mismas.
|
|
WO2013139744A1
(en)
|
2012-03-18 |
2013-09-26 |
Glaxosmithkline Biologicals S.A. |
Method of vaccination against human papillomavirus
|
|
EP2833900B1
(en)
|
2012-04-01 |
2018-09-19 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
EP2875041A2
(en)
|
2012-07-19 |
2015-05-27 |
Zoetis LLC |
Bovine influenza c virus compositions
|
|
AU2013295770A1
(en)
|
2012-07-27 |
2015-01-29 |
Zoetis Services Llc |
Tick toxin compositions
|
|
WO2014024026A1
(en)
|
2012-08-06 |
2014-02-13 |
Glaxosmithkline Biologicals S.A. |
Method for eliciting in infants an immune response against rsv and b. pertussis
|
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
|
SI2885007T1
(sl)
|
2012-08-16 |
2018-12-31 |
Pfizer Inc. |
Postopki in kompozicije glikokonjugacij
|
|
KR20140075196A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
EP3363806B1
(en)
|
2012-12-20 |
2022-11-16 |
Pfizer Inc. |
Glycoconjugation process
|
|
JP6497691B2
(ja)
|
2013-02-05 |
2019-04-10 |
日東電工株式会社 |
粘膜投与用ｗｔ１ペプチド癌ワクチン組成物
|
|
RU2014102941A
(ru)
|
2013-02-05 |
2015-08-10 |
Нитто Денко Корпорейшн |
Вакцинная композиция для введения через слизистую оболочку
|
|
EP2762158A1
(en)
|
2013-02-05 |
2014-08-06 |
Nitto Denko Corporation |
E75-vaccine composition for transdermal administration
|
|
KR102050931B1
(ko)
|
2013-02-05 |
2019-12-02 |
닛토덴코 가부시키가이샤 |
경피 투여용 ｗｔ1 펩티드 암 백신 테이프제
|
|
IN2014CH00395A
(https=)
|
2013-02-05 |
2015-04-03 |
Nitto Denko Corp |
|
|
EP2762154A3
(en)
|
2013-02-05 |
2015-01-21 |
Nitto Denko Corporation |
Vaccine composition for transdermal administration
|
|
EP3662927A3
(en)
|
2013-02-05 |
2020-10-21 |
Nitto Denko Corporation |
Vaccine composition
|
|
US20140220079A1
(en)
|
2013-02-05 |
2014-08-07 |
Nitto Denko Corporation |
Vaccine composition for mucosal administration
|
|
EP2762152A1
(en)
|
2013-02-05 |
2014-08-06 |
Nitto Denko Corporation |
WT1 peptide cancer vaccine composition for transdermal administration
|
|
KR20140100419A
(ko)
|
2013-02-05 |
2014-08-14 |
닛토덴코 가부시키가이샤 |
경피 투여용 ｗｔ1 펩티드 암 백신 조성물
|
|
US9802987B2
(en)
|
2013-03-08 |
2017-10-31 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
|
FI2970398T3
(fi)
|
2013-03-13 |
2024-08-06 |
Us Health |
Rsv f -prefuusioproteiineja ja niiden käyttö
|
|
ES2743465T3
(es)
|
2013-03-15 |
2020-02-19 |
Glaxosmithkline Biologicals Sa |
Composición que contiene derivados fosfato de aminoalquil glucosaminida tamponados y su uso para potenciar una respuesta inmunitaria
|
|
UY35418A
(es)
|
2013-03-15 |
2014-10-31 |
Glaxosmithkline Biolog Sa |
Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
|
|
JP2016512841A
(ja)
|
2013-03-15 |
2016-05-09 |
ゾエティス・サービシーズ・エルエルシー |
多価ワクチンによるｂ．トレハロシ感染に対するウシの干渉効果
|
|
EP2978447B1
(en)
|
2013-03-28 |
2019-05-08 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
|
US10260038B2
(en)
|
2013-05-10 |
2019-04-16 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
|
AU2014304545A1
(en)
|
2013-08-05 |
2016-02-25 |
Glaxosmithkline Biologicals S.A. |
Combination immunogenic compositions
|
|
US10392603B2
(en)
|
2013-08-30 |
2019-08-27 |
The Chemo-Sero-Therapeutic Research Institute |
Method of viral purification
|
|
RU2662968C2
(ru)
|
2013-09-08 |
2018-07-31 |
Пфайзер Инк. |
Иммуногенная композиция против neisseria meningitidis (варианты)
|
|
JP2015059577A
(ja)
|
2013-09-17 |
2015-03-30 |
Ntn株式会社 |
チェーン伝動装置
|
|
CN104436157A
(zh)
|
2013-09-23 |
2015-03-25 |
恩金生物有限公司 |
流感疫苗和治疗
|
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
|
WO2015095868A1
(en)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
|
BR112016016580B1
(pt)
|
2014-01-21 |
2024-01-09 |
Pfizer Inc |
Processo para a preparação de um conjugado imunogênico, conjugado imunogênico, composição imunogênica, e vacina
|
|
CN120718167A
(zh)
|
2014-01-21 |
2025-09-30 |
辉瑞大药厂 |
肺炎链球菌荚膜多糖及其缀合物
|
|
WO2016130569A1
(en)
|
2015-02-09 |
2016-08-18 |
Mj Biologics, Inc. |
A composition comprising pedv antigens and methods for making and using the composition
|
|
EP3104886B1
(en)
|
2014-02-14 |
2018-10-17 |
Pfizer Inc |
Immunogenic glycoprotein conjugates
|
|
US10821175B2
(en)
|
2014-02-25 |
2020-11-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
ES2702325T3
(es)
|
2014-03-11 |
2019-02-28 |
Univ Minnesota |
Vacunas contra el virus de la diarrea epidémica porcina y métodos de uso de las mismas
|
|
KR20160127828A
(ko)
|
2014-03-12 |
2016-11-04 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
면역원성 리포솜 제형
|
|
KR20160132088A
(ko)
|
2014-03-12 |
2016-11-16 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
점막 전달용 리포솜 조성물
|
|
US10426828B2
(en)
|
2014-04-03 |
2019-10-01 |
Biondvax Pharmaceuticals Ltd. |
Compositions of multimeric-multiepitope influenza polypeptides and their production
|
|
CN106659777A
(zh)
|
2014-06-13 |
2017-05-10 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合产品
|
|
AR101256A1
(es)
|
2014-07-21 |
2016-12-07 |
Sanofi Pasteur |
Composición vacunal que comprende ipv y ciclodextrinas
|
|
AR102548A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
|
|
MA40920A
(fr)
|
2014-11-07 |
2017-09-12 |
Takeda Vaccines Inc |
Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
|
|
JP2018509384A
(ja)
|
2015-01-06 |
2018-04-05 |
イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． |
リピドａ模倣体、調製方法、及びその使用
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
AU2016221318B2
(en)
|
2015-02-19 |
2020-06-25 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
|
AU2015384786B2
(en)
|
2015-03-03 |
2020-08-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Display platform from bacterial spore coat proteins
|
|
EP3268380B1
(en)
|
2015-03-12 |
2018-12-26 |
Zoetis Services LLC |
Pyolysin methods and compositions
|
|
PE20220774A1
(es)
|
2015-05-04 |
2022-05-16 |
Pfizer |
Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
|
|
MX375989B
(es)
|
2015-05-26 |
2025-03-07 |
Ohio State Innovation Foundation |
Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina.
|
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
|
EP3331565A1
(en)
|
2015-08-06 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Ltd |
Tlr4 agonists and compositions thereof and their use in the treatment of cancer
|
|
EP4137152A1
(en)
|
2015-08-14 |
2023-02-22 |
Zoetis Services LLC |
Mycoplasma bovis compositions
|
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
|
US10772946B2
(en)
|
2015-10-13 |
2020-09-15 |
Sanofi Pasteur |
Immunogenic compositions against S. aureus
|
|
TN2018000112A1
(en)
|
2015-10-29 |
2019-10-04 |
Novartis Ag |
Antibody conjugates comprising toll-like receptor agonist
|
|
TWI704154B
(zh)
|
2015-12-03 |
2020-09-11 |
英商葛蘭素史克智慧財產發展有限公司 |
新穎化合物
|
|
US20180318415A1
(en)
|
2015-12-08 |
2018-11-08 |
Glaxosmithkline Biologicals, Sa |
Novel adjuvant formulations
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
EP3402878A1
(en)
|
2016-01-11 |
2018-11-21 |
Zoetis Services LLC |
Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
|
|
WO2017137085A1
(en)
|
2016-02-11 |
2017-08-17 |
Sanofi Pasteur |
Meningitidis vaccines comprising subtilinases
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
JP2019510802A
(ja)
|
2016-04-07 |
2019-04-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
タンパク質調節物質として有用な複素環アミド
|
|
HRP20220936T1
(hr)
|
2016-04-07 |
2022-10-28 |
Glaxosmithkline Intellectual Property Development Limited |
Heterociklički amidi korisni kao modulatori proteina
|
|
CA3023157A1
(en)
|
2016-05-05 |
2017-11-09 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
WO2017210215A1
(en)
|
2016-05-31 |
2017-12-07 |
The Government Of The United States Of America As Represented By The Secretary Of The Army |
Zika virus vaccine and methods of production
|
|
EP3474890A1
(en)
|
2016-06-22 |
2019-05-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. |
Pneumococcal polysaccharide-protein conjugate composition
|
|
EP3269385A1
(en)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
|
JP2019521166A
(ja)
|
2016-07-20 |
2019-07-25 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
Ｐｅｒｋ阻害剤としてのイソキノリン誘導体
|
|
MX2019002178A
(es)
|
2016-08-23 |
2019-09-18 |
Glaxosmithkline Biologicals Sa |
Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
|
|
BR112019004913B1
(pt)
|
2016-09-16 |
2022-07-12 |
Infectious Disease Research Institute |
Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
|
|
EP3518966A1
(en)
|
2016-09-29 |
2019-08-07 |
GlaxoSmithKline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
KR20190090824A
(ko)
|
2016-12-01 |
2019-08-02 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
암을 치료하는 방법
|
|
BR112019011286A2
(pt)
|
2016-12-07 |
2019-10-15 |
Glaxosmithkline Biologicals S.A. |
métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
|
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
|
US11084850B2
(en)
|
2016-12-16 |
2021-08-10 |
The Pirbright Institute |
Recombinant prefusion RSV F proteins and uses thereof
|
|
GB201621686D0
(en)
|
2016-12-20 |
2017-02-01 |
Glaxosmithkline Biologicals Sa |
Novel methods for inducing an immune response
|
|
CN110225764A
(zh)
|
2017-01-31 |
2019-09-10 |
默沙东公司 |
制备多糖-蛋白缀合物的方法
|
|
AU2018215585B2
(en)
|
2017-01-31 |
2022-03-17 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
|
ES3048958T3
(en)
|
2017-01-31 |
2025-12-12 |
Merck Sharp & Dohme Llc |
Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
|
|
PT3585803T
(pt)
|
2017-02-24 |
2025-12-22 |
Merck Sharp & Dohme |
Formulações de vacina pneumocócica conjugada
|
|
GB201703529D0
(en)
|
2017-03-06 |
2017-04-19 |
Cambridge Entpr Ltd |
Vaccine composition
|
|
US10525119B2
(en)
|
2017-03-31 |
2020-01-07 |
Boston Medical Center Corporation |
Methods and compositions using highly conserved pneumococcal surface proteins
|
|
UA129243C2
(uk)
|
2017-04-19 |
2025-02-26 |
Інстітьют Фо Рісьорч Ін Біомедцін |
Антитіло, що зв'язується зі спорозоїтами p. falciparum
|
|
EP3615061A1
(en)
|
2017-04-28 |
2020-03-04 |
GlaxoSmithKline Biologicals S.A. |
Vaccination
|
|
US11389465B2
(en)
|
2017-05-01 |
2022-07-19 |
Vanderbilt University |
Phosphorylated hexaacyl disaccharides (PHADs) for treating or preventing infections
|
|
GB201707700D0
(en)
|
2017-05-12 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Dried composition
|
|
EP3630076A1
(en)
|
2017-05-30 |
2020-04-08 |
GlaxoSmithKline Biologicals SA |
Methods for manufacturing a liposome encapsulated rna
|
|
CA3063954A1
(en)
|
2017-05-30 |
2018-12-06 |
Glaxosmithline Biologicals S.A. |
Methods for manufacturing an adjuvant
|
|
WO2018237221A1
(en)
|
2017-06-23 |
2018-12-27 |
Nosocomial Vaccine Corporation |
IMMUNOGENIC COMPOSITIONS
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
PT3678654T
(pt)
|
2017-09-07 |
2024-08-05 |
Merck Sharp & Dohme Llc |
Polissacáridos pneumocócicos e sua utilização em conjugados imunogénicos de polissacárido-proteína transportadora
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
KR20250006307A
(ko)
|
2017-09-13 |
2025-01-10 |
사노피 파스퇴르 |
인간 시토메갈로바이러스 면역원성 조성물
|
|
CA3077337A1
(en)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting)
|
|
US20210238172A1
(en)
|
2017-10-05 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators and methods of using the same
|
|
JP7197880B2
(ja)
*
|
2017-10-19 |
2022-12-28 |
学校法人 名城大学 |
エステル化剤及びその利用
|
|
TWI725359B
(zh)
|
2017-12-06 |
2021-04-21 |
美商默沙東藥廠 |
包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
|
|
ES2985591T3
(es)
|
2018-02-12 |
2024-11-06 |
Inimmune Corp |
Ligandos de receptores tipo Toll
|
|
CA3091352A1
(en)
|
2018-02-21 |
2019-08-29 |
The University Of Montana |
Diaryl trehalose compounds and uses thereof
|
|
JP2021516045A
(ja)
|
2018-02-28 |
2021-07-01 |
ファイザー・インク |
Ｉｌ−１５バリアントおよびその使用
|
|
WO2019169313A1
(en)
|
2018-03-02 |
2019-09-06 |
The University Of Montana |
Immunogenic trehalose compounds and uses thereof
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
SI3797121T1
(sl)
|
2018-05-23 |
2024-09-30 |
Pfizer Inc. |
Protitelesa, specifična za CD3, in njihova uporaba
|
|
MX2020012607A
(es)
|
2018-05-23 |
2021-01-29 |
Pfizer |
Anticuerpos especificos para gucy2c y sus usos.
|
|
EP3574915A1
(en)
|
2018-05-29 |
2019-12-04 |
Neovacs |
Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
|
|
JP2021526831A
(ja)
|
2018-06-12 |
2021-10-11 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
アデノウイルスポリヌクレオチド及びポリペプチド
|
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
|
ES3038006T3
(en)
|
2018-07-31 |
2025-10-08 |
Glaxosmithkline Biologicals Sa |
Antigen purification method
|
|
WO2020030570A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
|
|
WO2020031087A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
|
CN111315407B
(zh)
|
2018-09-11 |
2023-05-02 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
|
WO2020109365A1
(en)
|
2018-11-29 |
2020-06-04 |
Glaxosmithkline Biologicals Sa |
Methods for manufacturing an adjuvant
|
|
GEAP202415690A
(en)
|
2018-12-19 |
2024-01-10 |
Merck Sharp & Dohme Llc |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
EP3897846A1
(en)
|
2018-12-21 |
2021-10-27 |
GlaxoSmithKline Biologicals SA |
Methods of inducing an immune response
|
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
|
MX2021014353A
(es)
|
2019-05-23 |
2022-02-21 |
The Univ Of Montana |
Adyuvantes de vacunas basados en ligandos de receptores tlr.
|
|
KR20220026585A
(ko)
|
2019-06-26 |
2022-03-04 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
Il1rap 결합 단백질
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
EP3999093A4
(en)
|
2019-07-19 |
2023-11-22 |
Merck Sharp & Dohme LLC |
ANTIGENIC E GLYCOPROTEIN POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
KR20220035457A
(ko)
|
2019-07-21 |
2022-03-22 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
치료 바이러스 백신
|
|
WO2021018941A1
(en)
|
2019-07-31 |
2021-02-04 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
|
BR112022001654A2
(pt)
|
2019-07-31 |
2022-07-12 |
Sanofi Pasteur Inc |
Composições conjugadas de proteinas de polissacarídeos pneumocócicos multivalentes e métodos de utilização dos mesmos
|
|
US12533318B2
(en)
|
2019-08-30 |
2026-01-27 |
Glaxosmithkline Biologicals Sa |
Jet mixing lipid nanoparticle manufacturing process
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
WO2021048081A1
(en)
|
2019-09-09 |
2021-03-18 |
Glaxosmithkline Biologicals Sa |
Immunotherapeutic compositions
|
|
JP7280387B2
(ja)
|
2019-09-27 |
2023-05-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
抗原結合タンパク質
|
|
EP4034157A1
(en)
|
2019-09-27 |
2022-08-03 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
|
US12533418B2
(en)
|
2019-11-22 |
2026-01-27 |
Glaxosmithkline Biologicals Sa |
Dosage and administration of a bacterial saccharide glycoconjugate vaccine
|
|
JP7369297B2
(ja)
|
2019-12-17 |
2023-10-25 |
ファイザー・インク |
Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
|
|
CN114981265B
(zh)
|
2019-12-18 |
2025-01-03 |
Ctxt私人有限公司 |
化合物
|
|
BR112022015994A2
(pt)
|
2020-02-13 |
2022-10-11 |
Univ Illinois |
Composição imunogênica multivalente, vetor recombinante, célula hospedeira recombinante, e, métodos para induzir uma resposta imune protetora e para imunizar um animal contra dirofilariose
|
|
WO2021209636A1
(en)
|
2020-04-16 |
2021-10-21 |
Par'immune Sas |
28 kda gst proteins from schistosoma for the treatment of vasculitis
|
|
EP4136095A1
(en)
|
2020-04-17 |
2023-02-22 |
Regents of the University of Minnesota |
Sars-cov-2 spike receptor binding domain and compositions and methods thereof
|
|
EP3900739A1
(en)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
|
|
US20230277657A1
(en)
|
2020-05-05 |
2023-09-07 |
Glaxosmithkline Biologicals Sa |
Microfluidic mixing device and methods of use
|
|
EP4158352A1
(en)
|
2020-06-01 |
2023-04-05 |
Loop Diagnostics, S.L. |
Method and kit for the early detection of sepsis
|
|
US20230234992A1
(en)
|
2020-06-05 |
2023-07-27 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
|
MX2022016181A
(es)
|
2020-06-22 |
2023-02-13 |
Sumitomo Pharma Co Ltd |
Adyuvante con actividad agonista del receptor tipo toll 4 (tlr4).
|
|
TW202216779A
(zh)
|
2020-07-17 |
2022-05-01 |
美商輝瑞股份有限公司 |
治療性抗體類和彼等之用途
|
|
KR20230056727A
(ko)
|
2020-08-26 |
2023-04-27 |
화이자 인코포레이티드 |
B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
|
|
EP4213943A1
(en)
|
2020-09-15 |
2023-07-26 |
The University Of Montana |
Compositions and methods targeting filamentous bacteriophage
|
|
KR20230110249A
(ko)
|
2020-09-17 |
2023-07-21 |
니오베크스 |
IgE-매개 염증성 장애를 치료하기 위한 IgE 단편을 포함하는 면역원성 생성물
|
|
KR20230106604A
(ko)
|
2020-11-11 |
2023-07-13 |
다이이찌 산쿄 가부시키가이샤 |
신규 아미노알킬글루코사미니드 4-인산 유도체
|
|
CA3202549A1
(en)
|
2020-12-02 |
2022-06-09 |
Glaxosmithkline Biologicals Sa |
Novel antigens
|
|
EP4032547A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Hsv1 fce derived fragements for the treatment of hsv
|
|
US20240115674A1
(en)
|
2021-02-03 |
2024-04-11 |
The Board Of Trustees Of The University Of Illinois |
Vaccine and methods for preventing filariasis and dirofilariasis
|
|
JP2024506364A
(ja)
|
2021-02-11 |
2024-02-13 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Ｈｐｖワクチンの製造
|
|
CN116917273A
(zh)
|
2021-03-02 |
2023-10-20 |
葛兰素史克知识产权发展有限公司 |
作为dnmt1抑制剂的经取代的吡啶
|
|
JP2024511831A
(ja)
|
2021-03-31 |
2024-03-15 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
抗原結合タンパク質およびそれらの組み合わせ
|
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
|
CN114318353B
(zh)
*
|
2021-12-27 |
2023-12-05 |
广东红日星实业有限公司 |
一种除灰剂及其制备方法和应用
|
|
WO2024069420A2
(en)
|
2022-09-29 |
2024-04-04 |
Pfizer Inc. |
Immunogenic compositions comprising an rsv f protein trimer
|
|
WO2025106603A1
(en)
|
2023-11-16 |
2025-05-22 |
Merck Sharp & Dohme Llc |
Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease
|
|
EP4656648A1
(en)
|
2024-05-31 |
2025-12-03 |
Consejo Superior De Investigaciones Científicas |
Immunomodulatory thiourea and urea carbohydrate compounds and uses thereof
|
|
WO2026038177A1
(en)
|
2024-08-16 |
2026-02-19 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|